Abstract Alcohol drinking patterns encompass various dimensions of consumption. However, most studies have focused narrowly on the quantity of alcohol consumed. This study aimed to identify alcohol-drinking patterns in middle-aged population using alcohol-related variables and to examine their relationship with coronary heart disease (CHD), stroke, and all-cause-mortality risk. The present population-based study included adults from the Danish Health Examination Survey (DANHES) cohort who were ≥40 years old and free of CHD and stroke at baseline (n = 46 141). Latent Class Analysis (LCA) was used to identify distinct subpopulations based on six alcohol-related variables (amount, frequency, binge episodes, type, within meals, at home and alone). Cox proportional hazard models were used to estimate hazard ratios (95% confidence interval) between drinking patterns and CHD, stroke, and all-cause mortality during a median follow-up of 11.8 years. Four classes of drinking patterns were identified in both sexes (labeled as “low drinkers,” “low-to-moderate drinkers,” “moderate-regular drinkers,” and “frequent-heavy drinkers”). The more frequent drinking pattern was a median of 3 (2–5) drinks per week. Frequent heavy drinking was associated with a higher risk of stroke. Individuals in the low-to-moderate male drinking class and the moderate-regular female drinking class not under heart medication had a lower risk of all-cause mortality than low-level drinkers. Four distinct drinking patterns were identified. Among individuals 40 years and older, frequent-heavy drinking was associated with a higher risk of stroke, while low-to-moderate regular drinking might be associated with a lower all-cause mortality risk compared to low drinkers.
Marta Trius-Soler, M. Guasch-Ferré, Cristina Valle-Hita et al.· European Journal of Public H...· 0 citations
Summary Background Type 2 diabetes is a major risk factor for cardiovascular disease, and reducing this excess risk is a central goal of clinical management. Sustained adherence to glucose-lowering medication is considered a key component of this strategy. However, long-term patterns of medication-taking behavior in real-world settings, and their relationship with cardiovascular outcomes, remain insufficiently characterized. Methods We conducted a nationwide cohort study of Danish adults with newly diagnosed type 2 diabetes who initiated non-insulin glucose-lowering medication between 2005 and 2012. Medication adherence was estimated from pharmacy dispensing data, and group-based trajectory modeling was used to identify longitudinal adherence patterns. The primary outcome was a composite cardiovascular outcome including ischemic heart disease, stroke, or heart failure. Associations between adherence trajectories and cardiovascular outcomes over 10 years of follow-up were assessed with Cox proportional-hazards models. Findings Among 79,510 individuals with newly diagnosed type 2 diabetes (median age, 61 (IQR: 52–69); 57% men), we identified three long-term adherence trajectories defined by high (n = 32,912; 41%), intermediate (n = 25,822; 33%), and low (n = 20,776; 26%) adherence. During follow-up, 15,276 cardiovascular events occurred. Compared with the high-adherence group, adjusted hazard ratios for the composite cardiovascular outcome were 1.07 (95% CI, 1.03–1.12) and 1.27 (95% CI, 1.21–1.33) in the intermediate- and low-adherence groups, respectively. Participants with high adherence remained free of cardiovascular events for an average of 220 more days (95% CI, 204–237) over 10 years. Associations were largely driven by ischemic heart disease, with no significant associations for heart failure. Interpretation Long-term adherence to glucose-lowering medication was associated with lower cardiovascular rate and longer event-free survival time among individuals with newly diagnosed type 2 diabetes. Funding Novo Nordisk Foundation and the European Innovation Council.
Lise B. Nielsen, A. Bartholdy, Tri-Long Nguyen et al.· The Lancet Regional Health -...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
